Phase 2/3CompletedAge-related condition
Montelukast in Parkinson Disease
Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease
- Sponsor
- Mostafa Bahaa (Academic or other)
- Enrolment
- 60 enrolled
- Conditions
- Parkinson Disease
- Interventions
- levodopa-carbidopa; Montelukast
- Ages
- adults, older adults
- Registry
- NCT06113640
Full record on ClinicalTrials.gov
From the registry
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.
Primary outcomes
- Change in unified parkison disease rating scale
History
Last registry update
Primary completion
Started
Registered